This move is archived. Current quotes and coverage live on the stock page.
Get CRDL alerts:
Cardiol Therapeutics Inc Class A (CRDL.TO) has seen a notable uptick in its stock price, closing up 2.31% in the last session.
In a market filled with volatility, Cardiol Therapeutics Inc Class A has managed to stand out by gaining 2.31% in a single trading day. This rise reflects investor optimism surrounding the company's recent developments and ongoing clinical trials.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$348.13M
52W high
$3.15
52W low
$1.23
1W change
+3.83%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 101.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+101.3% Upside
Current Price
C$2.98
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
72.8%
Annualized
90-Day Vol
57.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$3.56
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$3.16 | C$2.46 โ C$4.07 |
| 60 trading days | C$3.36 | C$2.35 โ C$4.79 |
| 90 trading days | C$3.56 | C$2.31 โ C$5.51 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: For Canadian investors, this positive move indicates growing confidence in Cardiol's future prospects, particularly as the company expands its clinical trial networks and prepares for significant presentations.
Market Cap Reaches CA$174.6 Million
With a market cap of CA$174.6 million, Cardiol Therapeutics is positioned in a niche sector that could see significant growth if clinical trials yield positive results.
Bull case
Cardiol's recent acceptance of its Phase II MAvERIC study results for publication has sparked interest among investors. This milestone shows the company's commitment to advancing heart disease treatments and could open doors for future funding and partnerships. Plus, the upcoming fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference is likely to attract more attention from investors.
Bear case
Despite the recent gains, Cardiol is still a small-cap company, which comes with risks. The lack of consistent media coverage and the speculative nature of biotech stocks could lead to fluctuations in the stock price.
Advertisement
Recent Developments Fueling Investor Interest
Cardiol's recent acceptance of its Phase II MAvERIC study results for publication has caught the attention of investors. This milestone not only highlights the company's ongoing commitment to advancing heart disease treatments but also positions it favorably for future funding and partnerships. Additionally, the upcoming fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference is expected to draw further interest from the investment community.
Market Performance and Future Outlook
The stock's recent performance, closing at CA$1.55, reflects a growing confidence in Cardiol's strategic direction. As the company expands its U.S. MAVERIC Phase III trial network, investors are hopeful for positive outcomes that could enhance the company's market position. However, potential investors should remain cautious, as the biotech sector can be unpredictable, and Cardiol's success hinges on the results of its ongoing trials.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
